ADReCS

Pharmaceutical Information

Drug Name	Hydroxyurea
Drug ID	BADD_D01110
Description	An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage	For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status	approved
ATC Code	L01XX05
DrugBank ID	DB01005
KEGG ID	D00341
MeSH ID	D006918
PubChem ID	3657
TTD Drug ID	D07CWD
NDC Product Code	0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII	X6Q56QN5QC
Synonyms	Hydroxyurea \| Hydroxycarbamid \| Oncocarbide \| Hydrea

Chemical Information

Molecular Formula	CH4N2O2
CAS Registry Number	127-07-1
SMILES	C(=O)(N)NO
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Lung infiltration	22.01.02.004	0.000168%		-
Lymphadenopathy	01.09.01.002	0.000168%		-
Lymphocytosis	01.02.01.003	0.000112%		-
Lymphoma	01.12.01.001; 16.20.01.001	0.000392%		-
Lymphopenia	01.02.02.002	0.000224%		-
Malaise	08.01.01.003	-	-
Malignant melanoma	16.03.01.001; 23.08.01.001	0.000112%		-
Methaemoglobinaemia	01.05.01.002	0.000168%
Mouth ulceration	07.05.06.004	0.000985%		-
Movement disorder	17.01.02.010	0.000224%		-
Mucosal inflammation	08.01.06.002	0.000280%		-
Muscle haemorrhage	12.01.07.016; 15.05.03.017; 24.07.01.037	0.000168%		-
Myelodysplastic syndrome	01.10.04.001; 16.01.04.001	0.000728%
Myelofibrosis	01.13.03.005; 16.21.03.001	0.002295%		-
Myocardial ischaemia	02.02.02.008; 24.04.04.010	0.000168%		-
Nail discolouration	23.02.05.001	0.000302%
Nail dystrophy	23.02.05.003	0.000246%		-
Nausea	07.01.07.001	-	-
Neoplasm	16.16.02.001	-	-	-
Nervous system disorder	17.02.10.001	0.000112%		-
Neuroendocrine carcinoma of the skin	05.08.01.009; 16.03.02.008; 23.08.02.008	0.000168%		-
Neuropathy peripheral	17.09.03.003	-	-	-
Neutropenia	01.02.03.004	-	-	-
Night sweats	08.01.03.031; 23.02.03.006	0.000224%		-
Oedema	08.01.07.006; 14.05.06.010	0.000560%		-
Oedema peripheral	02.05.04.007; 08.01.07.007; 14.05.06.011	0.000504%
Oesophageal carcinoma	07.21.06.001; 16.13.06.001	0.000112%		-
Oesophageal varices haemorrhage	07.12.01.003; 09.01.06.004; 24.07.02.022	0.000168%
Oligohydramnios	18.05.01.001	0.000112%		-
Oligospermia	21.03.03.005	-	-

The 6th Page First Pre 6 7 8 9 10 Next Last Total 13 Pages